GLP-1 Receptor Targeted PET Imaging Study for Diabetes

Study to Assess Beta Cell Mass in Diabetes Using GLP-1 Receptor Targeted PET Imaging

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051260068

Enrollment

Registered

2026-06-04

Start date

2026-06-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Diabetes

Interventions

PET imaging using 18F

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i. Individuals diagnosed with diabetes, as well as those clinically determined to be at high risk of developing diabetes. ii. Individuals aged 15 years or older.

Exclusion criteria

Exclusion criteria: i. Severe hepatic or renal impairment (AST or ALT > 200 U/L; eGFR < 15 mL/min/1.73 m2) ii. Currently using GLP-1-related products and unable to discontinue them iii. Not suitable for, or has contraindications to, exenatide administration iv. History of alcohol intolerance or severe intolerance to Tween 80 or metoclopramide v. Any other condition deemed inappropriate for participation in this study at the discretion of the principal investigator or sub-investigator(s)

Design outcomes

Primary

Measure	Time frame
Pancreatic beta-cell mass	—

Secondary

Measure	Time frame
Insulin secretion capacity, blood glucose fluctuations	—

Contacts

Public ContactHayao Yoshida

Kyoto University Graduate School of Medicine

tounaiei@kuhp.kyoto-u.ac.jp+81-75-751-3560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026